Jeffrey R. Aeschlimann

Pharm.D.

Department of Pharmacy Practice

---

Educational Background

• Post-doctoral Fellowship in Infectious Diseases Pharmacotherapy, Wayne State University, Detroit, MI, 1996-1998
• Doctor of Pharmacy, University of Utah, Salt Lake City, UT, 1994-1996
• Bachelor of Science in Pharmacy, University of Connecticut, Storrs, CT, 1998-1993

Professional Interests

• Quantification of the impact of multidrug efflux pump protein overproduction on antibiotic activity for Pseudomonas aeruginosa.
• Study of the mechanism(s) of antibiotic resistance of bacterial biofilms and the impact of “classic” antibiotic resistance on biofilm formation.
• Antibiotic pharmacodynamics for Gram-negative and Gram-Positive bacteria.
• Investigations of novel antibiotic dosing strategies to prevent or overcome antibiotic resistance in both the clinical and laboratory settings.
• Development and validation of novel in vitro systems that model human infections and predict in vivo antimicrobial activity.
• Use of active learning/problem-based learning for the teaching of Infectious Diseases Therapeutics to Pharm.D. students.

Selected Professional Accomplishments

• Aeschlimann JR and Bryers JD. Bacterial Biofilms in Human Infections. American College of Clinical Pharmacy Infectious Diseases Practice & Research Network Minisabbatical Award.
• Aeschlimann JR. Risk Factors and Clinical Outcomes in Patients with Infections due to Pseudomonas aeruginosa that Overexpress Efflux Pumps. Society of Infectious Diseases Pharmacists Research Award.
• Aeschlimann JR. The Effects of Vancomycin Crystalline Degradation Product 1 (CDP-1) on Selection of Vancomycin Resistance in Staphylococcus aureus. ACCP Aventis Infectious Diseases Research Award, University of Connecticut Faculty Large Grant Competition Award.
• Aeschlimann JR. Comparative Pharmacodynamics of Levofloxacin 500 and 750 mg every 24 hours, Alone and in Combinations with Other Antipseudomonal Antibiotics, against Pseudomonas aeruginosa. Ortho-McNeil Pharmaceuticals.
• Aeschlimann JR. Targeted Strategies to Prevent the Emergence of Ciprofloxacin-Resistant Pseudomonas aeruginosa. Bayer Pharmaceuticals.

Practice Site

• UConn Health Center
  Department of Pharmacy
  263 Farmington Avenue, MC2205
  Farmington, Connecticut 06030

Selected Publications

Publications on PubMed

Selected Presentations

• Aeschlimann JR. “Vancomycin Crystalline Degradation Product Can Help Select and Maintain Staphylococcus aureus Strains with Reduced Susceptibility to Vancomycin.”  In: Program and Abstracts of the 2003 American College of Clinical Pharmacy Annual Meeting, Atlanta, GA., November 2-5, 2003.
• Aeschlimann JR. “Risk Factors and Clinical Outcomes of Patients with Infections Caused by Efflux Pump Overproducing Pseudomonas aeruginosa.” Presented at: Society of Infectious Diseases Pharmacists Annual Meeting, Chicago, IL, 9/27/03.
• Aeschlimann JR, Milliken S, Bryant D, Doyle CJ, and D’Souza NK. “Adaptive Resistance to Aminoglycosides is Lost upon Overproduction of MexXY-OprM or MexAB-OprM Efflux Pumps in Pseudomonas aeruginosa.” In: Programs & Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, Sept 14-17, 2003.
• Aeschlimann JR, Doyle CJ, and D’Souza NK. “Antipseudomonal Activity and Resistance Prevention for Different Multidrug Efflux Pump (MDEP) Substrates Combined with Levofloxacin in an In Vitro Infection Model (IVIM).” In: Programs & Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, Sept 14-17, 2003.
• Aeschlimann JR and D’Souza NK. “Comparative Antipseudomonal Activity of High-Dose Levofloxacin (L) and Ciprofloxacin (C) in an In Vitro High-Inoculum Infection Model.” In: Program and Abstracts of the 103rd General Meeting of the American Society for Microbiology, Washington, D.C., May 17-21, 2003.